Advanced bladder cancer

Therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil

S. D. Williams, J. P. Donohue, Lawrence Einhorn

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nineteen patients with unresectable or metastatic urothelial cancer were treated with the combination of cis-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil. One patient died within 2 weeks of therapy and one patient had no measurable disease, leaving 18 patients evaluable for survival and toxicity and 17 patients evaluable for response. Eleven patients (65%) achieved a partial remission with attendant clinical improvement, with a median duration of 25 weeks. All nonresponders have died, with a median survival of 17 weeks. The median survival of responding patients was 40 weeks, with two patients alive at 33+ and 63+ weeks. Of particular interest are three patients who had resections of residual pelvic disease after significant regression with chemotherapy. One of these patients remains disease-free at 63+ weeks. Toxicity was significant but generally manageable.

Original languageEnglish
Pages (from-to)1573-1576
Number of pages4
JournalCancer Treatment Reports
Volume63
Issue number9-10
StatePublished - 1979

Fingerprint

Urinary Bladder Neoplasms
Fluorouracil
Doxorubicin
Cisplatin
Therapeutics
Survival
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Advanced bladder cancer : Therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil. / Williams, S. D.; Donohue, J. P.; Einhorn, Lawrence.

In: Cancer Treatment Reports, Vol. 63, No. 9-10, 1979, p. 1573-1576.

Research output: Contribution to journalArticle

@article{d37456479e484f75ba29a17c6d3cf265,
title = "Advanced bladder cancer: Therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil",
abstract = "Nineteen patients with unresectable or metastatic urothelial cancer were treated with the combination of cis-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil. One patient died within 2 weeks of therapy and one patient had no measurable disease, leaving 18 patients evaluable for survival and toxicity and 17 patients evaluable for response. Eleven patients (65{\%}) achieved a partial remission with attendant clinical improvement, with a median duration of 25 weeks. All nonresponders have died, with a median survival of 17 weeks. The median survival of responding patients was 40 weeks, with two patients alive at 33+ and 63+ weeks. Of particular interest are three patients who had resections of residual pelvic disease after significant regression with chemotherapy. One of these patients remains disease-free at 63+ weeks. Toxicity was significant but generally manageable.",
author = "Williams, {S. D.} and Donohue, {J. P.} and Lawrence Einhorn",
year = "1979",
language = "English",
volume = "63",
pages = "1573--1576",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9-10",

}

TY - JOUR

T1 - Advanced bladder cancer

T2 - Therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil

AU - Williams, S. D.

AU - Donohue, J. P.

AU - Einhorn, Lawrence

PY - 1979

Y1 - 1979

N2 - Nineteen patients with unresectable or metastatic urothelial cancer were treated with the combination of cis-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil. One patient died within 2 weeks of therapy and one patient had no measurable disease, leaving 18 patients evaluable for survival and toxicity and 17 patients evaluable for response. Eleven patients (65%) achieved a partial remission with attendant clinical improvement, with a median duration of 25 weeks. All nonresponders have died, with a median survival of 17 weeks. The median survival of responding patients was 40 weeks, with two patients alive at 33+ and 63+ weeks. Of particular interest are three patients who had resections of residual pelvic disease after significant regression with chemotherapy. One of these patients remains disease-free at 63+ weeks. Toxicity was significant but generally manageable.

AB - Nineteen patients with unresectable or metastatic urothelial cancer were treated with the combination of cis-dichlorodiammineplatinum(II), Adriamycin, and 5-fluorouracil. One patient died within 2 weeks of therapy and one patient had no measurable disease, leaving 18 patients evaluable for survival and toxicity and 17 patients evaluable for response. Eleven patients (65%) achieved a partial remission with attendant clinical improvement, with a median duration of 25 weeks. All nonresponders have died, with a median survival of 17 weeks. The median survival of responding patients was 40 weeks, with two patients alive at 33+ and 63+ weeks. Of particular interest are three patients who had resections of residual pelvic disease after significant regression with chemotherapy. One of these patients remains disease-free at 63+ weeks. Toxicity was significant but generally manageable.

UR - http://www.scopus.com/inward/record.url?scp=0018568984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018568984&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1573

EP - 1576

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9-10

ER -